Idioma:

Predominance of MGMT promoter methylation among Pakistani glioblastoma patients

Muhammad, Noor ; Fasih, Samir ; Malik, Bilal ; Hameed, Shahid ; Loya, Asif ; Rashid, Muhammad Usman

Molecular biology reports, 2024-12, Vol.51 (1), p.433-433, Article 433 [Periódico revisado por pares]

Dordrecht: Springer Netherlands

Texto completo disponível

Citações Citado por

Enviar para

Título:
Predominance of MGMT promoter methylation among Pakistani glioblastoma patients
Autor: Muhammad, Noor ; Fasih, Samir ; Malik, Bilal ; Hameed, Shahid ; Loya, Asif ; Rashid, Muhammad Usman
Assuntos: Adolescent ; Adult ; Aged ; Animal Anatomy ; Animal Biochemistry ; Antineoplastic Agents, Alkylating - therapeutic use ; Biomedical and Life Sciences ; Brain Neoplasms - genetics ; Brain Neoplasms - pathology ; Chemotherapy ; DNA ; DNA methylation ; DNA Methylation - genetics ; DNA methyltransferase ; DNA Modification Methylases - genetics ; DNA Repair Enzymes - genetics ; Female ; Glioblastoma ; Glioblastoma - pathology ; Histology ; Humans ; Life Sciences ; Male ; Methylguanine ; Middle Aged ; Morphology ; O6-methylguanine-DNA methyltransferase ; Original Article ; Pakistan ; Patients ; Population studies ; Radiation therapy ; Retrospective Studies ; Tumor Suppressor Proteins - genetics ; Young Adult
É parte de: Molecular biology reports, 2024-12, Vol.51 (1), p.433-433, Article 433
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Background Glioblastoma multiforme (GBM), the most prevalent subgroup of neuroepithelial tumors, is characterized by dismal overall survival (OS). Several studies have linked O6-methylguanine-DNA-methyltransferase ( MGMT ) promoter methylation to OS in GBM patients. However, MGMT methylation frequencies vary geographically and across ethnicities, with limited data for South Asian populations, including Pakistan. This study aimed to analyze MGMT promoter methylation in Pakistani GBM patients. Methods Consecutive primary GBM patients diagnosed ≥ 18 years-of-age, with no prior chemotherapy or radiotherapy history, were retrospectively selected. DNA was isolated from formalin-fixed-paraffin-embedded tissues. MGMT promoter methylation was analyzed using methylation-specific PCR. Clinical, pathological, and treatment data were assessed using Fisher’s exact/Chi-squared tests. OS was calculated using Kaplan-Meier analysis in SPSS 27.0.1. Results The study included 48 GBM patients, comprising 38 (79.2%) males and 10 (20.8%) females. The median diagnosis age was 49.5 years (range 18–70). MGMT methylation was observed in 87.5% (42/48) of all cases. Patients with MGMT methylation undergoing radiotherapy or radiotherapy plus chemotherapy exhibited significantly improved median OS of 7.2 months (95% CI, 3.7–10.7; P < 0.001) and 16.9 months (95% CI, 15.9–17.9; P < 0.001), respectively, compared to those undergoing surgical resection only (OS: 2.2 months, 95% CI, 0.8–3.6). Conclusion This is the first comprehensive study highlighting a predominance of MGMT methylation in Pakistani GBM patients. Furthermore, our findings underscore the association of MGMT methylation with improved OS across diverse treatment modalities. Larger studies are imperative to validate our findings for better management of Pakistani GBM patients.
Editor: Dordrecht: Springer Netherlands
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Resultado 1 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Predominance of MGMT promoter methylation among Pakistani glioblastoma patients

Muhammad, Noor ; Fasih, Samir ; Malik, Bilal ; Hameed, Shahid ; Loya, Asif ; Rashid, Muhammad Usman

Dordrecht: Springer Netherlands

Buscando em bases de dados remotas. Favor aguardar.